Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation
Cristina Arpa, Hagar Khalid, Shruti Chandra, Siegfried Wagner, Katrin Fasler, Livia Faes, Pakinee Pooprasert, Reena Chopra, Gabriella Moraes, Konstantinos Balaskas, Pearse Keane, Sobha Sivaprasad & Dun Jack Fu
Background: To describe 10-year trends in visual outcomes, anatomical outcomes, and treatment burden of patients receiving anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). Methods: Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling ≤ 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA...
1 citation reported since publication in 2020.
418 views reported since publication in 2020.
These counts follow the
COUNTER Code of Practice,
meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
28 downloads reported since publication in 2020.
These counts follow the
COUNTER Code of Practice,
meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?